For instance, HDAC inhibition has repeatedly been shown to enhance NIS levels and radioiodine uptake [30, 31], with Vorinostat (SAHA, FDA‐approved) being particularly effective in both well‐differentiated and undifferentiated thyroid cancer models when combined with chloroquine or VCP inhibitors to prevent NIS internalization and degradation [22, 23]. Here, VCP is linked to thyroid cancer.